Finally, the clinical efficacy of anti-IL-5-targeted therapy at approved doses for severe asthma (benralizumab 30 mg, mepolizumab 100 mg) and high (benralizumab 100 mg, mepolizumab 300 mg) doses were included in the integrated analysis of COPD patients with increased peripheral blood eosinophils. Here, IL5 is linked to chronic obstructive pulmonary disease.